Skip to main content

Management

Peter Wolpert, CEO and founder, M.Sc. Eng., M.Sc. Econ.
Born 1969. Has worked for the company since 2006. Peter Wolpert has more than 15 years' experience as a CEO, strategy consultant and entrepreneur, and is a member of the board of MedUniverse AB. He was a co-founder of Accuro Immunology, Ibility and Viscogel, CEO of Athera Biotechnologies and a strategy consultant at McKinsey & Co.

Shareholding: 435 399 shares through Wolco Invest AB and 180 000 employee stock options (180 000 shares may be subscribed to, based on the employee stock options).
 

Shaw Sorooshian, Vice President, Chief Medical Officer, MD, FFPM
Born 1964. Has worked for the company since 2018. Shaw Sorooshian has 14 years’ experience in the biopharmaceutical industry, having worked in positions of increasing seniority in Organon Labs, Lundbeck, Shire and Sobi. Dr Sorooshian spent 18 years in clinical practice, and has undergone specialist training in anaesthesiology and pharmaceutical medicine.
 
Shareholding: 5 000 shares and 20 000 performance share units

Anna Ljung, CFO , M.Sc. Econ.
Born 1980. Has worked for the company since 2006. Anna Ljung has served as the CFO of Athera Biotechnologies AB and Lipopetide AB, and worked as an independent consultant in the field of technology licensing. She is also a board member of Saniona AB.
 
Shareholding: 12 000 shares, 14 500 performance share units and 110 000 employee stock options (110 000 shares may be subscribed to, based on the employee stock options).

Jeff Vernimb, Vice President, Global Consumer Health B. Sc.
Born in 1963. Has worked for the company since 2014. Jeff Vernimb has headed Moberg Pharma´s North American operations since joining company and was appointed Vice President, Global Consumer Health in late 2017 to assume added responsability for global OTC marketing and sales. Previous experience includes senior level sales, marketing and Rx-to-OTC switch roles in both large and smaller entrepreneurial consumer healthcare companies including Pfizer, Novartis, Dynova Labs and Insight Pharmaceuticals.

Shareholding: 14 329 shares, 56 250 performance share units and 170 000 employee stock options (170 000 shares may be subscribed to, based on the employee stock options).
Torbjörn Wärnheim, Vice President Pharmaceutical Innovation and Development
Born 1958. Has worked for the company since 2013. Prior to his position with Moberg, Torbjörn Wärnheim was Vice President R&D at Fresenius Kabi. In addition to this he has held senior level positions at ACO HUD and Pharmacia & Upjohn among others. Torbjörn Wärnheim has a broad experience of pharmaceutical development of Rx- and OTC-products, and is associate professor at Royal Institute of Technology (KTH), Stockholm, with a research background within surface chemistry and physical chemistry of lipids.

Shareholding: 4 500 aktier, 15 526 performance share units och 36 500 employee stock options (36 500 shares may be subscribed to, based on the employee stock options).

 

Mark Beveridge, Vice President Finance , B.Com, GradDipCA

Born 1978. Has worked for the company since 2015. Mark Beveridge has more than 15 years professional experience in providing accounting and assurance services, primarily with Crowe Horwath and Visma Services, and worked as an independent consultant in financial management, transaction services and strategic system implementations.

Shareholding: 26 537 shares, 27 500 performance share units and 25 500 employee stock options (25 500 shares may be subscribed to, based on the employee stock options).

 

Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.